DelveInsight Business Research, a leading healthcare-focused market research and consulting firm, notes a significant development in the Acute-on-Chronic Liver Failure (ACLF) treatment landscape. On March 9, 2026, GENFIT (Euronext: GNFT) announced that the FDA granted Orphan Drug Designation (ODD) to G1090N, a proprietary reformulation of nitazoxanide (NTZ), for the treatment of ACLF.
ACLF is a rapidly progressing, life-threatening syndrome that develops in patients with underlying cirrhosis or chronic liver disease, characterized by acute hepatic decompensation, multiorgan failure, and high short-term mortality. Despite its severity, no FDA-approved pharmacological therapy currently exists for ACLF, making this regulatory designation a landmark step in a historically underserved therapeutic area.
The ODD confers meaningful clinical and commercial advantages, including eligibility for FDA regulatory guidance, certain user-fee reductions, and seven years of U.S. market exclusivity upon potential approval, incentives that may substantially reshape the competitive dynamics of the ACLF market.
Download Our Comprehensive Acute-on-Chronic Liver Failure Market Report to Understand the Full Competitive Landscape.
Clinical Context & Acute-on-Chronic Liver Failure Pipeline Progress
G1090N is GENFIT’s lead investigational program within its ACLF pipeline. The candidate has demonstrated a favorable safety and tolerability profile in Phase 1 studies conducted in healthy volunteers, alongside compelling anti-inflammatory activity observed in ex vivo assays using samples from both healthy volunteers and cirrhotic donors. These findings establish a scientifically robust foundation for advancing the program into Phase 2 clinical development, which GENFIT has targeted for initiation in the second half of 2026.
The significance of this designation extends beyond a single candidate. GENFIT is one of the most active players in the ACLF pipeline, with multiple assets in development, including VS-01, a scavenging liposomal therapy currently being evaluated in the international UNVEIL-IT Phase 2 proof-of-concept study, and additional early-stage programs targeting distinct pathophysiological pathways. Other notable investigational candidates in the broader ACLF space include Albumin 5% (PE-A 5%) from Grifols Therapeutics, currently in Phase 3 clinical evaluation.
The convergence of multiple pipeline assets reaching mid-to-late-stage development simultaneously signals that the Acute-on-Chronic Liver Failure treatment paradigm may be poised for a significant transformation within this decade.
Request a free sample of DelveInsight’s ACLF Market Report to learn more about the key pipeline, epidemiology & forecast data.
Acute-on-Chronic Liver Failure Market Opportunity & Epidemiology
According to DelveInsight’s analysis, approximately 62K total cases of ACLF were recorded across the seven major markets (7MM) — comprising the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan — in 2023. The United States accounted for roughly 21% of this total, with EU4 and the UK representing approximately 73% of cases. Germany alone recorded nearly 17K cases, making it the single largest market by patient volume in Europe.
The ACLF market is projected to grow at a compound annual growth rate (CAGR) of approximately 11% through the 2026–2034 forecast period, driven by a rising incidence of chronic liver diseases, including cirrhosis, hepatitis B and C, and metabolic dysfunction-associated steatohepatitis (MASH), that serve as primary precipitating conditions for ACLF. The anticipated introduction of novel pharmacological therapies, including G1090N and VS-01, is expected to catalyze commercial market expansion significantly.
With liver transplantation remaining the only definitive current treatment option, the commercial opportunity for effective, scalable pharmacological intervention is substantial and largely untapped.
Unlock the full ACLF Market Forecast across 7 Major Markets, including market size, share & growth projections.
Strategic Implications For Pharma Executives
For pharmaceutical executives evaluating portfolio strategy, business development opportunities, or competitive positioning, the GENFIT Orphan Drug Designation milestone warrants close attention. The ACLF space is transitioning from a near-empty pipeline to a multi-player competitive arena within a relatively compressed timeframe. Early movers stand to benefit from orphan drug exclusivity, premium pricing potential, and first-to-market advantages in a condition with significant unmet need and high patient acuity.
DelveInsight’s Acute-on-Chronic Liver Failure (ACLF) Market Insights, Epidemiology, and Market Forecast report provides a rigorous, data-driven intelligence platform for decision-makers. The report delivers country-level epidemiology segmentation; current and emerging therapy profiles with safety and efficacy data; conjoint and SWOT analyses; KOL perspectives drawn from 50+ expert interviews across leading hepatology centers in the US, Europe, and Japan; and detailed market-size projections segmented by therapy and geography through 2034.
This intelligence is directly actionable for asset prioritization, licensing evaluations, competitive benchmarking, and market entry planning across the 7MM.
Speak to a DelveInsight analyst to get expert insights on ACLF market dynamics & investment opportunities.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services